Skip to content
Screener

Aquestive Therapeutics, Inc. AQST Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Viatris logo
ViatrisVTRS
$0.010.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$00.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0.010.0%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
AbbVie logo
AbbVieABBV
AptarGroup logo
AptarGroupATR

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Operating income-$8.2M+27.7%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$494.34M+28.9%
Enterprise value$459.23M+20.0%
P/S9.1×+0.5×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%
Debt / equity-1.1×
Current ratio7.2×+3.7×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001398733-26-000042
Line itemJune 30,2026December 31,2025
Total liabilities188,690194,087
Contingencies (Note 20)
Stockholders’ deficit:
Common Stock, $0.001 par value. Authorized 250,000,000 shares; 125,511,648 and 122,044,299 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively126122
Additional paid-in capital421,207413,214
Accumulated deficit(477,919)(446,998)
Total stockholders’ deficit(56,586)(33,662)
Total liabilities and stockholders’ deficit$132,104$160,425

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Aquestive Therapeutics, Inc.'s common stock, par value (in dollars per share)?
Aquestive Therapeutics, Inc. (AQST) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Aquestive Therapeutics, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
Aquestive Therapeutics, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Aquestive Therapeutics, Inc.'s common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Aquestive Therapeutics, Inc.'s common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude